Oncology · KRAS InhibitorTrial Updateclinicalmid-term

Phase I/II Study of GDC-7035 in Advanced Solid Tumors with KRAS G12D Mutation

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/21/2026, 6:31:08 PM

Assessment confidence: 92% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase I/II study of GDC-7035 by Genentech is significant as it targets the KRAS G12D mutation, a critical area in oncology. Success in this trial could solidify Genentech's position in the competitive landscape of KRAS inhibitors, impacting their overall portfolio and market strategy. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 21 ranked evidence items (21 high-relevance).

Strategic Assessment

Success in this trial could enhance Genentech's portfolio in precision oncology and strengthen its market position against competitors developing KRAS inhibitors. The strongest clinical anchor is A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ClinicalTrials.gov), mechanism alignment (io ); sponsor/company relevance (astrazeneca). In Oncology · KRAS Inhibitor, 3 regulatory and 5 competitive items passed relevance filtering for Roche.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — mechanism alignment (kras); entity match (roche). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial positions Genentech in the competitive landscape of KRAS-targeted therapies, which are gaining traction in oncology.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Sponsor/company relevance (Roche); Patient population match (advanced). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes will inform future regulatory submissions and labeling for GDC-7035, influencing its path to market and compliance with safety standards.

Key Risks

Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If GDC-7035 demonstrates efficacy, it could lead to increased market share for Genentech in the oncology sector, particularly in precision medicine, enhancing revenue potential.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors.
Lead sponsor: BeOne Medicines. The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Upside for Roche may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial progress, safety data, and preliminary efficacy results as they become available.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAhigh relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (approval)
FDA document
View source
Drug Trials Snapshots: YARTEMLEA
FDAhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis); Patient population match (advanced)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Mechanism alignment (KRAS); Entity match (roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Mechanism alignment (KRAS); Entity match (roche)
Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise
Humanexa Signalshigh relevance
Mechanism alignment (KRAS); Sponsor/company relevance (Roche)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Entity match (roche)

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedhigh relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.
PubMedhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
xinguangA preliminary characterization of PI4K/PIPK alterations across solid tumors: an exploratory framework for prognostic and therapeutic stratification.
PubMedhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Roche
GDC-7035

Commercial impact

medium

If GDC-7035 demonstrates efficacy, it could lead to increased market share for Genentech in the oncology sector, particularly in precision medicine, enhancing revenue potential.

Regulatory impact

medium

The trial's outcomes will inform future regulatory submissions and labeling for GDC-7035, influencing its path to market and compliance with safety standards.

What to watch

Monitor trial progress, safety data, and preliminary efficacy results as they become available.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.